focus -WSS

focus

author：explore 2025-09-28 20:32:58 - browse：174

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Bill would stop addiction treatment from triggering child abuse inquiry

explore

focus

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

FDA advisory panel to debate high blood pressure devices

Phenylephrine and the overlooked value of the placebo effect

CDC says it’s too soon to assess risk posed by Covid subvariant

Health officials lay out plans to cope with respiratory virus season

A Q&A with the global head of Boehringer Ingelheim's innovation unit

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Alkermes shareholders re

Roche's accidental data boosts hopes for anti

Activists slam private health insurers over coverage restrictions

Bill would stop addiction treatment from triggering child abuse inquiry

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

In age of alternative facts, a scholarly course on calling out crap

Vivek Ramaswamy made waves in the debate, much as in biotech

Medicare details structure of new drug price negotiation program

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

Why age limits for politicians are a terrible idea

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wegovy improves function in certain heart failure patients

CDC says it’s too soon to assess risk posed by Covid subvariant

Why Charlie Gard's case is so disturbing to Americans

knowledge

explore

focus

Wikipedia